Every line above is re-verified against the primary agency source before each update. What the July 2026 FDA vote did and did not do →
What BPC-157 is
BPC-157 is a synthetic peptide derived from a sequence identified in gastric juice. It is widely marketed for tissue repair. It has no FDA-approved indication and is not available as an approved prescription medicine in the United States.
What the human evidence shows
The published literature is dominated by rodent and in-vitro studies. Registered human trials are few and small, and the outcomes reported in animal models have not been reproduced in adequately powered human trials. Animal and laboratory findings are not evidence of human benefit, and this guide does not present them as such.
What FDA actually assessed
This is the detail most coverage omits. When FDA brought BPC-157 to its Pharmacy Compounding Advisory Committee in July 2026, the published agenda names the use evaluated: ulcerative colitis. Not tendon repair, not ligament injury, not athletic recovery — the uses it is almost universally sold for. A favourable outcome on the indication FDA reviewed would say nothing about the indication buyers have in mind.
Evidence limitations
Several specific limitations recur across the available literature:
- Most studies use animal models at doses and routes not comparable to human marketing claims.
- Human reports are small and frequently uncontrolled.
- Publication and reporting bias in this literature has not been assessed systematically.
- Marketed material is not manufactured to pharmaceutical standards, so what was studied may not be what is sold.
Known and plausible risks
Risk information is limited precisely because controlled human data is limited. FDA’s own published language is that it has identified "no, or only limited, safety-related information" and therefore "lacks sufficient information to know whether the drug would cause harm when administered to humans." Absence of reported harm in a small literature is not evidence of safety, and additional risks apply to any injectable prepared outside a licensed pharmacy.
How far up the evidence hierarchy this reaches
Registered human trials exist but are few and small; the literature is dominated by rodent and in-vitro work, which is where the tendon-repair claims come from.
Where it sits on the compounding pathway
What it is sold for, against what the evidence shows
Marketing claims on the left, in the terms sellers use. What the human literature actually supports on the right.
| Marketed for | What the evidence shows | Verdict |
|---|---|---|
| Tendon and ligament healing | Rodent and in-vitro studies. No adequately powered human trial. | No human evidence |
| Gut and ulcer healing | The indication FDA reviewed in July 2026 was ulcerative colitis; the supporting literature is still largely preclinical. | Partly supported |
| Faster recovery from athletic injury | No human trials, and prohibited at all times in sport. | No human evidence |
Where to go next
No dosing, cycling, stacking, reconstitution or administration instructions appear anywhere on this site, and this page links to no page selling an unapproved injectable. Questions about how a substance would be used belong with a licensed clinician who has evaluated you.